a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The clinical trial was conducted in a cohort of young, high-risk myeloma patients who were
designed to receive a combination of high-dose chemotherapy with allogeneic or autologous
hematopoietic stem cell transplantation. The objective was to assess the progression free
survival (PFS), overall survival (OS),and overall response rate (ORR) of the overall
treatment.